Across TCGA pan-cancer cohorts, FAM3C Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM3C data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FAM3C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM3C expression acts as an unfavorable survival marker.

LIHC and BLCA are the cancer types where FAM3C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	III,IV	0.076	0.360	.001	24	view →
BLCA	OS	Median	All	0.069	0.688	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: FAM3C tumor-vs-normal RNA expression · all FAM3C data types